<DOC>
	<DOCNO>NCT00884481</DOCNO>
	<brief_summary>The primary objective trial observe Multiple Sclerosis ( MS ) relate fatigue treatment Tysabri measure change fatigue scale motor cognitive function ( FMSC ) course 12 month . The secondary objective : To investigate change fatigue , capacity work , Health Related Quality Life ( HRQol ) , sleepiness , cognitive impairment , physically activity induced exhaustion , speed walking , status MS disease progression amount walk different time point initiation Tysabri treatment participant diagnose Relapsing-Remitting Multiple Sclerosis ( RRMS ) . Changes fatigue measure 3 , 6 9 month , whereas change capacity work , HRQoL , sleepiness , cognitive impairment , physical activity induce exhaustion , speed walking , status MS disease progression amount walk measure 6 12 month . To investigate correlation fatigue cognitive impairment , depression physically activity induce exhaustion status MS disease progression participant baseline , 6 12 month treatment Tysabri document change fatigue related medication .</brief_summary>
	<brief_title>Effects Tysabri ( BG00002 ) Over 12 Months MS Related Fatigue Participants With RRMS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Tysabri prescribe accord national guideline yet start treatment Signed informed consent form FSMC sum score &gt; 43 baseline ( mild fatigue ) Key FSMC sum score 43 baseline History treatment Tysabri EDSS &gt; 6 baseline Amphetamine medication Major depression NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>